{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,26]],"date-time":"2026-02-26T14:04:17Z","timestamp":1772114657363,"version":"3.50.1"},"reference-count":20,"publisher":"MDPI AG","issue":"14","license":[{"start":{"date-parts":[[2024,7,10]],"date-time":"2024-07-10T00:00:00Z","timestamp":1720569600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cancers"],"abstract":"<jats:p>Introduction: The treatment of patients with hematological malignancies and acute arterial thrombosis (ATE) is challenging due to the risk of bleeding complications during treatment. Data on the incidence and risk factors for ATE in this group are very limited. Aims: We aimed to evaluate the incidence and risk factors for ATE in patients with acute leukemia (AL) and lymphoid malignancies. Material and Methods: Patients with acute leukemia (AL), lymphoid malignancies, and ATE diagnosed following cancer diagnosis, who were treated and followed at the Department of Hematology, Karolinska University Hospital, 2005\u20132020, were candidates for inclusion in this study. Retrospective data on malignancy, ATE, and risk factors were collected. Results: No differences in either the 15-year incidence of ATE (1.4%) nor in the risk factors for cardiovascular disease (CVD) between patients with AL and lymphoid malignancies and ATE were found. ATE at diagnosis was more frequent in patients with AL and lymphoid malignancies (excluding chronic lymphatic leukemia, CLL). Conclusions: Patients with AL and lymphoid malignancies have a similar risk of ATE when compared to each other and the general population, regardless of platelet levels. No difference could be found in the presence of CVD risk factors between patients with AL and lymphoid malignancies presenting with ATE.<\/jats:p>","DOI":"10.3390\/cancers16142511","type":"journal-article","created":{"date-parts":[[2024,7,11]],"date-time":"2024-07-11T11:30:55Z","timestamp":1720697455000},"page":"2511","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Incidence and Risk Factors for Arterial Thrombosis in Patients with Acute Leukemia and Lymphoid Malignancies: A Retrospective Single-Center Study"],"prefix":"10.3390","volume":"16","author":[{"ORCID":"https:\/\/orcid.org\/0009-0005-3682-1315","authenticated-orcid":false,"given":"Jenna","family":"Hellman","sequence":"first","affiliation":[{"name":"Department of Molecular Medicine and Surgery, Karolinska Institute, 17177 Solna, Sweden"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9069-1903","authenticated-orcid":false,"given":"Roza","family":"Chaireti","sequence":"additional","affiliation":[{"name":"Department of Molecular Medicine and Surgery, Karolinska Institute, 17177 Solna, Sweden"},{"name":"Department of Hematology, Karolinska University Hospital, 17176 Stockholm, Sweden"},{"name":"Department of Medicine, Karolinska Institute, 17177 Solna, Sweden"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1968","published-online":{"date-parts":[[2024,7,10]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"1419","DOI":"10.3324\/haematol.2018.197814","article-title":"Arterial thrombosis and cancer: The neglected side of the coin of Trousseau syndrome","volume":"103","year":"2018","journal-title":"Haematologica"},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"386","DOI":"10.1177\/1078155219851540","article-title":"The incidence and risk factors of thrombosis and the need for thromboprophylaxis in lymphoma and leukemia patients: A 9-year single-center experience","volume":"26","author":"Albayrak","year":"2020","journal-title":"J. Oncol. Pharm. Pract."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"926","DOI":"10.1016\/j.jacc.2017.06.047","article-title":"Risk of Arterial Thromboembolism in Patients With Cancer","volume":"70","author":"Navi","year":"2017","journal-title":"J. Am. Coll. Cardiol."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"1549","DOI":"10.3324\/haematol.2018.192419","article-title":"Frequency, risk factors, and impact on mortality of arterial thromboembolism in patients with cancer","volume":"103","author":"Grilz","year":"2018","journal-title":"Haematologica"},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"484","DOI":"10.1200\/JCO.2005.03.8877","article-title":"Thromboembolism in hospitalized neutropenic cancer patients","volume":"24","author":"Khorana","year":"2006","journal-title":"J. Clin. Oncol."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1007\/s11883-018-0702-5","article-title":"Chemotherapeutic Agents and the Risk of Ischemia and Arterial Thrombosis","volume":"20","author":"Hassan","year":"2018","journal-title":"Curr. Atheroscler. Rep."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1016\/j.clml.2014.05.003","article-title":"Thrombosis and hemostatic abnormalities in hematological malignancies","volume":"14","author":"Colombo","year":"2014","journal-title":"Clin. Lymphoma Myeloma Leuk."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"65","DOI":"10.5758\/vsi.2016.32.2.65","article-title":"Recurrent Arterial Thrombosis as a Presenting Feature of a Variant M3-Acute Promyelocytic Leukemia","volume":"32","author":"Chotai","year":"2016","journal-title":"Vasc. Specialist Int."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"596","DOI":"10.1002\/ajh.23158","article-title":"Bleeding and thrombosis in acute promyelocytic leukemia","volume":"87","author":"Choudhry","year":"2012","journal-title":"Am. J. Hematol."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"1305","DOI":"10.1111\/jth.14475","article-title":"Risk of thromboembolic and bleeding outcomes following hematological cancers: A Danish population-based cohort study","volume":"17","author":"Adelborg","year":"2019","journal-title":"J. Thromb. Haemost."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"S68","DOI":"10.1016\/S0049-3848(20)30400-X","article-title":"Anticoagulant and antiplatelet treatment in cancer patients with thrombocytopenia","volume":"191","author":"Leader","year":"2020","journal-title":"Thromb. Res."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"2119","DOI":"10.1111\/jth.13140","article-title":"Definition of clinically relevant non-major bleeding in studies of anticoagulants in atrial fibrillation and venous thromboembolic disease in non-surgical patients: Communication from the SSC of the ISTH","volume":"13","author":"Kaatz","year":"2015","journal-title":"J. Thromb. Haemost."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"1340","DOI":"10.1161\/CIRCRESAHA.115.306841","article-title":"Global Burden of Thrombosis: Epidemiologic Aspects","volume":"118","author":"Wendelboe","year":"2016","journal-title":"Circ. Res."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"7","DOI":"10.3322\/caac.21708","article-title":"Cancer statistics, 2022","volume":"72","author":"Siegel","year":"2022","journal-title":"CA Cancer J. Clin."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"1575","DOI":"10.1038\/bjc.2015.94","article-title":"Lymphoma incidence, survival and prevalence 2004\u20132014: Sub-type analyses from the UK\u2019s Haematological Malignancy Research Network","volume":"12","author":"Smith","year":"2015","journal-title":"Br. J. Cancer"},{"key":"ref_16","unstructured":"(2022, June 21). Statistical Databases on Incidence of Stroke and Myocardial Infarction in Sweden. Available online: https:\/\/www.socialstyrelsen.se\/en\/statistics-and-data\/statistics\/statistical-databases\/."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"1985","DOI":"10.1111\/j.1538-7836.2005.01467.x","article-title":"The risk of thrombosis in patients with acute leukemia: Occurrence of thrombosis at diagnosis and during treatment","volume":"3","author":"Rossi","year":"2005","journal-title":"J. Thromb. Haemost."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"3488","DOI":"10.1093\/eurheartj\/ehx531","article-title":"The management of antiplatelet therapy in acute coronary syndrome patients with thrombocytopenia: A clinical conundrum","volume":"38","author":"McCarthy","year":"2017","journal-title":"Eur. Heart J."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"e750","DOI":"10.1097\/HS9.0000000000000750","article-title":"EHA Guidelines on Management of Antithrombotic Treatments in Thrombocytopenic Patients With Cancer","volume":"6","author":"Falanga","year":"2022","journal-title":"HemaSphere"},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"2120","DOI":"10.1001\/jama.2011.1654","article-title":"Number of coronary heart disease risk factors and mortality in patients with first myocardial infarction","volume":"306","author":"Canto","year":"2011","journal-title":"JAMA"}],"container-title":["Cancers"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2072-6694\/16\/14\/2511\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T15:13:05Z","timestamp":1760109185000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2072-6694\/16\/14\/2511"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,7,10]]},"references-count":20,"journal-issue":{"issue":"14","published-online":{"date-parts":[[2024,7]]}},"alternative-id":["cancers16142511"],"URL":"https:\/\/doi.org\/10.3390\/cancers16142511","relation":{},"ISSN":["2072-6694"],"issn-type":[{"value":"2072-6694","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,7,10]]}}}